Abstract:Background Oxidative stress (OS) and neuroinflammatory pathways play an important role in the pathophysiology of schizophrenia. The present study investigated the relationship between OS, inflammatory cytokines, and clinical features in male patients with treatment-resistant schizophrenia (TRS). Method We measured plasma OS parameters, including manganese-superoxide dismutase (Mn-SOD), copper/zinc-containing SOD (CuZn-SOD), total-SOD (T-SOD), malondialdehyde (MDA), catalase (CAT), and glutathione peroxidase (GSH-Px); and serum inflammatory cytokines, including interleukin (IL)− 1α, IL-6, tumor necrosis factor-alpha (TNF-α), and interferon (IFN)-γ, from 80 male patients with chronic schizophrenia (31 had TRS and 49 had chronic stable schizophrenia (CSS)), and 42 healthy controls. The severity of psychotic symptoms was evaluated using the Positive and Negative Syndrome Scale (PANSS). Results Compared with healthy controls, plasma Mn-SOD, CuZn-SOD, T-SOD, GSH-Px, and MDA levels were significantly lower, while CAT and serum IL-6 levels were higher in both TRS and CSS male patients (all P < 0.05). Significant differences in the activities of CAT ( F = 6.068, P = 0.016) and IL-6 levels ( F = 6.876, P = 0.011) were observed between TRS and CSS male patients after analysis of covariance. Moreover, a significant positive correlation was found between IL-6 levels and PANSS general psychopathology subscores ( r = 0.485, P = 0.006) and between CAT activity and PANSS total scores ( r = 0.409, P = 0.022) in TRS male patients. CAT and IL-6 levels were predictors for TRS. Additionally, in chronic schizophrenia patients, a significant positive correlation was observed between IL-6 and GSH-Px ( r = 0.292, P = 0.012), and the interaction effect of IL-6 and GSH-Px was positively associated with PANSS general psychopathology scores ( r = 0.287, P = 0.014). Conclusion This preliminary study indicated that variations in OS and inflammatory cytokines may be involved in psychopathology for patients with chronic schizophrenia, especially in male patients with TRS.

The Novel Oxidative Stress Marker Thioredoxin is Increased in First-Episode Schizophrenic Patients.

Imbalanced Free Radicals and Antioxidant Defense Systems in Schizophrenia: A Comparative Study

Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls.

Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia

Superoxide Dismutase and Cytokines in Chronic Patients with Schizophrenia: Association with Psychopathology and Response to Antipsychotics

Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study

Sex Difference in the Interrelationship Between TNF-α and Oxidative Stress Status in First-Episode Drug-Naïve Schizophrenia.

Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms

Plasma Total Antioxidant Status and Cognitive Impairments in First-Episode Drug-Naïve Patients with Schizophrenia.

Effect of Risperidone Treatment on Serum Activity of Superoxide Dismutase and Levels of Malondialdehyde and S100B in First-Episode Schizophrenic Patients

Oxidative Stress and Emergence of Psychosis

Catalase and interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients

Serum Metabolomic Profiling Based on FT-ICR-MS: Do the Dysfunctions of Metabolic Pathways Reveal a Universal Risk of Oxidative Stress in Schizophrenia?

Serum Levels of Oxidants and Protein S100B Were Associated in the First-Episode Drug Naïve Patients with Schizophrenia

Effects of Antipsychotic Treatment on S100B and Oxidative Stress in Patients with Schizophrenia

Thioredoxin is a Novel Diagnostic and Prognostic Marker in Patients with Ischemic Stroke.

Antioxidant Enzymes and Lipid Peroxidation in Different Forms of Schizophrenia Treated with Typical and Atypical Antipsychotics.

Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase

Variations to plasma H 2 O 2 levels and TAC in chronical medicated and treatment-resistant male schizophrenia patients: Correlations with psychopathology

Serum Metabolomic Profiling Based on Fourier Transform-Ion Cyclotron Resonance-Mass Spectrometry: Do the Dysfunctions of Metabolic Pathways Reveal a Universal Risk of Oxidative Stress in Schizophrenia?

A Meta-Analysis of Oxidative Stress Markers in Schizophrenia